Abstract
Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a tumor suppressor and a negative regulator of several receptor tyrosine kinases. The molecular mechanisms by which LRIG1 mediates its tumor suppressor effects and regulates receptor tyrosine kinases remain incompletely understood. Here, we performed a yeast two-hybrid screen to identify novel LRIG1-interacting proteins and mined data from the BioPlex (biophysical interactions of ORFeome-based complexes) protein interaction data repository. The putative LRIG1 interactors identified in the screen were functionally evaluated using a triple co-transfection system in which HEK293 cells were co-transfected with platelet-derived growth factor receptor α, LRIG1, and shRNAs against the identified LRIG1 interactors. The effects of the shRNAs on the ability of LRIG1 to down-regulate platelet-derived growth factor receptor α expression were evaluated. On the basis of these results, we present an LRIG1 protein interaction network with many newly identified components. The network contains the apparently functionally important LRIG1-interacting proteins RAB4A, PON2, GAL3ST1, ZBTB16, LRIG2, CNPY3, HLA-DRA, GML, CNPY4, LRRC40, and LRIG3, together with GLRX3, PTPRK, and other proteins. In silico analyses of The Cancer Genome Atlas data sets revealed consistent correlations between the expression of the transcripts encoding LRIG1 and its interactors ZBTB16 and PTPRK and inverse correlations between the transcripts encoding LRIG1 and GLRX3. We further studied the LRIG1 function–promoting paraoxonase PON2 and found that it co-localized with LRIG1 in LRIG1-transfected cells. The proposed LRIG1 protein interaction network will provide leads for future studies aiming to understand the molecular functions of LRIG1 and the regulation of growth factor signaling.
Highlights
Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a tumor suppressor and a negative regulator of several receptor tyrosine kinases
Ϩ ϩ ϩ a High-confidence LRIG1-interacting proteins according to Ref. 20 and 21 data sets were retrieved from the BioGrid portal. b Total number of specific interactions of the respective bait in Refs. 20 and 21 combined. c The effect on LRIG1 function was defined as positive (ϩ) or negative (Ϫ) when the corresponding shRNA yielded a significant increase or decrease, respectively, in the PDGFRA level upon co-transfection of human embryonic kidney 293 (HEK293) cells with PDGFRA and LRIG1 in the triple co-transfection system. d The effect on the LRIG1 level was defined as positive (ϩ) or negative (Ϫ) when the corresponding shRNA yielded a significant increase or decrease, respectively, in the
We investigated possible correlations between the expression of the transcripts encoding the respective LRIG1 interactor and LRIG1 in The Cancer Genome Atlas (TCGA) data sets to determine whether the expression of any of the LRIG1 interactors was associated with LRIG1 expression
Summary
Number of Effect on Effect on LRIG1 amino acidsa independent clonesb LRIG1 functionc leveld. C The effect on LRIG1 function was defined as positive or negative (Ϫ) when the corresponding shRNA yielded a significant increase or decrease, respectively, in the PDGFRA level upon co-transfection of HEK293 cells with PDGFRA and LRIG1 in the triple co-transfection system. By testing different transfection reagents, total amounts of plasmid DNA, and ratios of the included plasmids and by considering the resulting cell viability, the level of LRIG1-induced down-regulation of PDGFRA, and the level of shRNA target down-regulation efficiency, we arrived at the protocol described under “Experimental procedures.”. Because the devised triple co-transfection system allowed us to simultaneously monitor LRIG1-mediated downregulation of PDGFRA expression while the expression of a third protein was down-regulated with shRNA, we decided to use this experimental system to evaluate the functional importance of the LRIG1-interacting proteins. Cells were transfected with each combination of plasmids three independent times by an investigator who was blinded to the order and identity of the
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.